Daijiworld Media Network - New York
New York, Apr 6: Medical Microinstruments Inc (MMI) has received clearance from the US Food and Drug Administration to begin human trials of a robotic-assisted surgical approach aimed at treating Alzheimer's disease, marking a significant shift from conventional drug-based therapies.
The approval, granted under an Investigational Device Exemption (IDE), positions MMI among early innovators exploring surgical interventions for a condition traditionally addressed through pharmaceuticals.
At the core of the initiative is a feasibility study titled REMIND (Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease). The trial will utilise the company’s Symani Surgical System, a robotic platform designed for supermicrosurgery, combined with specialised microsurgical techniques.
According to the company, the study will primarily assess device-related serious adverse events within 30 days of the procedure, while secondary parameters such as imaging results, biomarkers and cognitive outcomes will be monitored over a six-month period.
The procedure targets deep cervical lymph nodes (dCLNs) in the neck, aiming to restore disrupted lymphatic drainage pathways. This approach is based on emerging research indicating that lymphatic vessels connected to the brain play a crucial role in clearing waste proteins such as amyloid beta and tau, which are commonly associated with Alzheimer’s.
MMI CEO Mark Toland described the development as a breakthrough moment. “This approval signals what is possible when advanced technology and research converge. We are entering a new era where robotic precision could help unlock novel treatment pathways for diseases like Alzheimer’s,” he said.
The procedure requires exceptional precision, as lymphatic vessels involved can be as small as 0.2 millimetres in diameter. MMI’s robotic system is designed to assist surgeons in creating highly accurate connections between lymphatic vessels or nodes and nearby veins.
The company is collaborating with research institutions across the US and Europe for the study, which could potentially redefine future treatment strategies for neurodegenerative diseases.